Here's Why Novavax (NVAX) is a Strong Momentum Stock

Zacks identifies Novavax (NVAX) as a strong momentum stock, despite its Zacks Rank #3 (Hold), based on its B-rated Momentum and VGM Scores. The biotechnology firm has seen its shares rise 10% in the last four weeks, accompanied by three analyst upgrades for fiscal 2025 earnings estimates, pushing the Zacks Consensus Estimate up by $0.20 to $2.68 per share, and boasts an impressive average earnings surprise of +335.8%.

Analysis

Novavax (NVAX) presents a notable case for momentum-focused investors, supported by several quantitative signals despite its neutral Zacks #3 (Hold) rank. The stock is assigned a 'B' for both its Momentum and overall VGM Style Scores, indicating favorable characteristics for short-term outperformance. This is corroborated by recent price action, with shares appreciating 10% over the past four weeks. More significantly, forward-looking sentiment from analysts is improving; three analysts have revised their fiscal 2025 earnings estimates higher within the last 60 days. This has lifted the Zacks Consensus Estimate for FY2025 by $0.20 to $2.68 per share. The company's track record of significantly outperforming expectations, evidenced by an average earnings surprise of +335.8%, further strengthens the argument that current estimates may still have upside.

Key Decisions for Investors

• Investors with a momentum-based strategy should consider NVAX for their watchlist, given the combination of positive price trends, a 'B' Momentum Score, and upward revisions to forward earnings estimates.
• It is important to weigh the positive momentum factors against the stock's neutral Zacks #3 (Hold) rank, which suggests a lack of a strong 'Buy' signal from a broader fundamental perspective.
• Monitor for continued upward revisions in analyst earnings estimates, as this appears to be a primary driver of positive sentiment and could signal a potential future upgrade to its Zacks Rank.